Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.34 |
| ▸ | THRA | P10827 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25758670 | 0.97 | MAPT (0.37) | MAPTNPSR1L3MBTL1MAPK1GRIK1 | |
| SCHEMBL25761405 | 0.95 | MAPT (0.35) | MAPTNPSR1L3MBTL1MAPK1GRIK1 | |
| SCHEMBL25757497 | 0.94 | MAPT (0.36) | MAPTNPSR1L3MBTL1MAPK1GRIK1 | |
| SCHEMBL25757485 | 0.90 | MAPT (0.34) | MAPTNPSR1L3MBTL1MAPK1GRIK1 | |
| SCHEMBL25761358 | 0.89 | CPB2 (0.38) | MAPTNPSR1L3MBTL1MAPK1GRIK1 | |
| SCHEMBL25757701 | 0.89 | MAPT (0.33) | MAPTNPSR1L3MBTL1MAPK1PRKCD | |
| SCHEMBL3229092 | 0.78 | HSD11B1 (0.35) | L3MBTL1 | |
| SCHEMBL25758657 | 0.77 | S1PR1 (0.42) | MAPTNPSR1L3MBTL1MAPK1PRKCD | |
| SCHEMBL25234506 | 0.74 | NAAA (0.55) | MAPTNPSR1GRIK1GRIK2NAAA | |
| SCHEMBL25283102 | 0.74 | NAAA (0.55) | MAPTNPSR1GRIK1GRIK2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | MAPT 4102/4885NPSR1 2262/4885L3MBTL1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.